Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
HemoGenyx Pharmaceuticals Plc ( (GB:HEMO) ) has issued an update.
Hemogenyx Pharmaceuticals announced that the Data Safety Monitoring Board has approved the continuation of its Phase I clinical trial for HG-CT-1, a CAR-T therapy for acute myeloid leukemia, allowing dose escalation and the start of pediatric recruitment. This milestone signifies a de-risking step in the therapy’s development, potentially enhancing its efficacy and paving the way for broader clinical validation, which could positively impact the company’s market position and investor interest.
More about HemoGenyx Pharmaceuticals Plc
Hemogenyx Pharmaceuticals is a publicly traded biopharmaceutical company headquartered in London, with subsidiaries in New York City. The company focuses on developing new medicines and treatments for blood and autoimmune diseases, utilizing distinct product candidates and platform technologies for novel product development.
Average Trading Volume: 124,365
Technical Sentiment Signal: Buy
Current Market Cap: £46.54M
Learn more about HEMO stock on TipRanks’ Stock Analysis page.